1e
19
1
49
2
2
18
1b
1d
18
39
52
1d
2 29
1d
25
Warren S. Pear, M.D., Ph.D.
78
52
Gaylord P. and Mary Louise Harnwell Professor
28
70
3
78
Abramson Cancer Center Member, University of Pennsylvania
8b
Attending Physician, Molecular Pathology, Hospital of the University of Pennsylvania
83
Member Abramson Family Cancer Research Institute, University of Pennsylvania
80
Institute for Immunology, Executive Committee, University of Pennsylvania
92
Co-Program Leader, Cancer Immunobiology, Abramson Cancer Center, University of Pennsylvania
a1
Director, Cancer & Immunopathology Division, Dept of Pathology & Lab Medicine, University of Pennsylvania
7b
Deputy Director, Institute of Immunology, University of Pennsylvania
11
Department: Pathology and Laboratory Medicine
4
1
23
1f
Graduate Group Affiliations
8
b
-
6b
- Cell and Molecular Biology 41
- Bioengineering 5c
- Immunology e
1d
46
Contact information
3c
4
3
3
1d
3c
556 BRB II/III
37 421 Curie Blvd.
Philadelphia, PA 19104-6160
26
37 421 Curie Blvd.
Philadelphia, PA 19104-6160
30
Office: (215) 573-7764
34 Fax: (215) 573-6725
24
99
34 Fax: (215) 573-6725
24
Email:
wpear@pennmedicine.upenn.edu
12
wpear@pennmedicine.upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
96 Search PubMed for articles
8f Training Program in Immunobiology of Normal and Neoplastic Lymphocytes
5d PEAR LAB WEBSITE
c
4
b
1f
96 Search PubMed for articles
8f Training Program in Immunobiology of Normal and Neoplastic Lymphocytes
5d PEAR LAB WEBSITE
c
13
Education:
21 a B.A. 16 (Economics) c
3b Williams College, Williamstown, MA, 1980.
21 a Ph.D. 29 (Tumor Biology - George Klein) c
40 Karolinska Institute, Stockholm, Sweden, 1987.
21 a M.D. c
3f University of Rochester, Rochester, NY, 1989.
c
3
3
3
3
8a
Permanent link21 a B.A. 16 (Economics) c
3b Williams College, Williamstown, MA, 1980.
21 a Ph.D. 29 (Tumor Biology - George Klein) c
40 Karolinska Institute, Stockholm, Sweden, 1987.
21 a M.D. c
3f University of Rochester, Rochester, NY, 1989.
c
2 29
21
1e
1d
24
5e
4f Tumor Biology, Development, Stem Cells, Hematopoiesis, Immune Function
8
140 Research Techniques: In vivo and in vitro models of hematopoiesis, transformation and immunity, retroviral transduction, bone marrow transplantation, ES cell culture and differentiation, cDNA cloning, cell sorting, video microscopy, knockout and RNAi technology, ChIP-Seq and global transcription analysis
8
26 Description of Research
607 A major area of interest of this laboratory is understanding the processes that lead to the development and differentiation of mature hematopoietic cells from a single hematopoietic stem cell. We are particularly interested in studying the processes that perturb these normal processes and cause leukemia. A primary focus of the laboratory is the role that Notch proteins play in regulating hematopoietic cell fate decisions and cancer. Notch proteins are a conserved family of receptors that regulate cell fate decisions in organisms ranging from Drosophila to humans. Using a variety of in vitro and in vivo approaches, we have shown that Notch proteins are key regulators of multiple hematopoietic cell fates. These include establishment of the T cell lineage and helper type 2 T cells. We are presently undertaking studies to identify the signaling pathways that control these and other cell fate decisions in hematopoiesis. In addition to their role in normal hematopoiesis, dysregulation of Notch signaling is a cause of human leukemia. We have developed a mouse model of Notch-related leukemia and are using this to study the signaling pathways that lead to oncogenic transformation. Using gene array and bioinformatics approaches, we have identified several direct transcriptional targets of Notch signaling that appear to mediate its effects in normal development and leukemia. In addition, we are developing and testing ways to block Notch signaling that may be useful in treating leukemia and other Notch-dependent diseases.
8
20 Rotation Projects
239 1. Characterization of Notch transcriptional targets in hematopoiesis and leukemia. This project will characterize potential direct transcriptional targets of Notch signaling that we have identified in a microarray screen. The project will involve verifying that these are direct transcriptional targets using chromatin immunoprecipitation (ChIP), EMSA, and reporter assays and then testing whether these targets are functionally important using retroviral transduction, apoptosis, proliferation, and differentiation in both primary and established cell lines.
8
222 2. Identification of genes that potentiate Notch transforming activity. We have induced a number of Notch T cell leukemias using retroviruses that express activated forms of Notch1. The retroviral vectors also contain enhancer elements that can activate transcription of genes in the vicinity of their integration site. We have established techniques to rapidly clone the genes that are activated by retroviral vector integration and will use both in vitro and in vivo assays to determine if they synergize with Notch to induce leukemia.
8
117 3. We have identified Tribbles as a novel oncogene in acute myelogenous leukemia. Very little is know about Tribbles function. This project will use biochemical and functional assays to determine the function of Tribbles in leukemia and normal hematopoietic development.
8
17 Lab personnel:
2b Katherine Forsyth, Graduate Student
24 Ethan Mack, Graduate Student
31 Vicki Mercado, Post-baccalaureate Scholar
31 Caitlin O'Neill, Administrative Assistant
31 Yumi Ohtani, Senior Research Investigator
2c Jelena Petrovic, Postdoctoral Fellow
24 Kelly Rome, Graduate Student
28 Sarah Stein, Postdoctoral Fellow
31 Lanwei Xu, Research Specialist/Lab Manager
65
1a 29
27
Description of Research Expertise
2b Research Interests4f Tumor Biology, Development, Stem Cells, Hematopoiesis, Immune Function
8
140 Research Techniques: In vivo and in vitro models of hematopoiesis, transformation and immunity, retroviral transduction, bone marrow transplantation, ES cell culture and differentiation, cDNA cloning, cell sorting, video microscopy, knockout and RNAi technology, ChIP-Seq and global transcription analysis
8
26 Description of Research
607 A major area of interest of this laboratory is understanding the processes that lead to the development and differentiation of mature hematopoietic cells from a single hematopoietic stem cell. We are particularly interested in studying the processes that perturb these normal processes and cause leukemia. A primary focus of the laboratory is the role that Notch proteins play in regulating hematopoietic cell fate decisions and cancer. Notch proteins are a conserved family of receptors that regulate cell fate decisions in organisms ranging from Drosophila to humans. Using a variety of in vitro and in vivo approaches, we have shown that Notch proteins are key regulators of multiple hematopoietic cell fates. These include establishment of the T cell lineage and helper type 2 T cells. We are presently undertaking studies to identify the signaling pathways that control these and other cell fate decisions in hematopoiesis. In addition to their role in normal hematopoiesis, dysregulation of Notch signaling is a cause of human leukemia. We have developed a mouse model of Notch-related leukemia and are using this to study the signaling pathways that lead to oncogenic transformation. Using gene array and bioinformatics approaches, we have identified several direct transcriptional targets of Notch signaling that appear to mediate its effects in normal development and leukemia. In addition, we are developing and testing ways to block Notch signaling that may be useful in treating leukemia and other Notch-dependent diseases.
8
20 Rotation Projects
239 1. Characterization of Notch transcriptional targets in hematopoiesis and leukemia. This project will characterize potential direct transcriptional targets of Notch signaling that we have identified in a microarray screen. The project will involve verifying that these are direct transcriptional targets using chromatin immunoprecipitation (ChIP), EMSA, and reporter assays and then testing whether these targets are functionally important using retroviral transduction, apoptosis, proliferation, and differentiation in both primary and established cell lines.
8
222 2. Identification of genes that potentiate Notch transforming activity. We have induced a number of Notch T cell leukemias using retroviruses that express activated forms of Notch1. The retroviral vectors also contain enhancer elements that can activate transcription of genes in the vicinity of their integration site. We have established techniques to rapidly clone the genes that are activated by retroviral vector integration and will use both in vitro and in vivo assays to determine if they synergize with Notch to induce leukemia.
8
117 3. We have identified Tribbles as a novel oncogene in acute myelogenous leukemia. Very little is know about Tribbles function. This project will use biochemical and functional assays to determine the function of Tribbles in leukemia and normal hematopoietic development.
8
17 Lab personnel:
2b Katherine Forsyth, Graduate Student
24 Ethan Mack, Graduate Student
31 Vicki Mercado, Post-baccalaureate Scholar
31 Caitlin O'Neill, Administrative Assistant
31 Yumi Ohtani, Senior Research Investigator
2c Jelena Petrovic, Postdoctoral Fellow
24 Kelly Rome, Graduate Student
28 Sarah Stein, Postdoctoral Fellow
31 Lanwei Xu, Research Specialist/Lab Manager
65
Description of Clinical Expertise
72 I am an attending physician in Molecular Pathology within the Center for Personalized Diagnostics.1a 29
23
e9 Li T, Bou-Dargham MJ, Fultang N, Li X, Pear WS, Sun H, Chen YH.: c-Rel-dependent monocytes are potent immune suppressor cells in cancer. J Leukoc Biol Jun 2022.
199 Gómez Atria D, Gaudette BT, Londregan J, Kelly S, Perkey E, Allman A, Srivastava B, Koch U, Radtke F, Ludewig B, Siebel CW, Ryan RJ, Robertson TF, Burkhardt JK, Pear WS, Allman D, Maillard I.: Stromal Notch ligands foster lymphopenia-driven functional plasticity and homeostatic proliferation of naïve B cells. J Clin Invest May 2022.
133 Zhou Y, Petrovic J, Zhao J, Zhang W, Bigdeli A, Zhang Z, Berger SL, Pear WS, Faryabi RB.: EBF1 nuclear repositioning instructs chromatin refolding to promote therapy resistance in T leukemic cells. Mol Cell 82(5): 1003-1020, Mar 2022.
108 Schwartz GW, Zhou Y, Petrovic J, Pear WS, Faryabi RB.: TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes. Cell Rep 36: 109575, Aug 2021.
1a5 Zheng Q, Capell BC, Parekh V, O'Day C, Atillasoy C, Bashir HM, Yeh C, Shim EH, Prouty SM, Dentchev T, Lee V, Wushanley L, Kweon Y, Suzuki-Horiuchi Y, Pear W, Grice EA, Seykora JT.: Whole-Exome and Transcriptome Analysis of UV-Exposed Epidermis and Carcinoma In Situ Reveals Early Drivers of Carcinogenesis. J Invest Dermatol 141: 295-307, Feb 2021.
1c9 Kobia FM, Preusse K, Dai Q, Weaver N, Hass MR, Chaturvedi P, Stein SJ, Pear WS, Yuan Z, Kovall RA, Kuang Y, Eafergen N, Sprinzak D, Gebelein B, Brunskill EW, Kopan R.: Notch dimerization and gene dosage are important for normal heart development, intestinal stem cell maintenance, and splenic marginal zone B-cell homeostasis during mite infestation. PLoS Biol 18: e3000850, Oct 2020.
c1 Zhang W, Pear WS.: MYC degradation via AURKB inhibition: a new brake in the path to T-ALL. Blood Sci 2: 68-69, May 2020.
183 Rome KS, Stein SJ, Kurachi M, Petrovic J, Schwartz GW, Mack EA, Uljon S, Wu WW, DeHart AG, McClory SE, Xu L, Gimotty PA, Blacklow SC, Faryabi RB, Wherry EJ, Jordan MS, Pear WS.: Trib1 regulates T cell differentiation during chronic infection by restraining the effector program. J Exp Med 217: e20190888, May 2020.
14e Schwartz Gregory W, Zhou Yeqiao, Petrovic Jelena, Fasolino Maria, Xu Lanwei, Shaffer Sydney M, Pear Warren S, Vahedi Golnaz, Faryabi Robert B: TooManyCells identifies and visualizes relationships of single-cell clades. Nature Methods 17(4): 405-413, April 2020.
2c
7
1d
1f
Selected Publications
172 McClory SE, Bardhan O, Rome KS, Giles JR, Baxter AE, Xu L, Gimotty PA, Faryabi RB, Wherry EJ, Pear WS, Jordan MS.: The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR(+) CD8(+) effector state, and its deletion improves checkpoint blockade. Cell Rep 42: 112905, Jul 2023.e9 Li T, Bou-Dargham MJ, Fultang N, Li X, Pear WS, Sun H, Chen YH.: c-Rel-dependent monocytes are potent immune suppressor cells in cancer. J Leukoc Biol Jun 2022.
199 Gómez Atria D, Gaudette BT, Londregan J, Kelly S, Perkey E, Allman A, Srivastava B, Koch U, Radtke F, Ludewig B, Siebel CW, Ryan RJ, Robertson TF, Burkhardt JK, Pear WS, Allman D, Maillard I.: Stromal Notch ligands foster lymphopenia-driven functional plasticity and homeostatic proliferation of naïve B cells. J Clin Invest May 2022.
133 Zhou Y, Petrovic J, Zhao J, Zhang W, Bigdeli A, Zhang Z, Berger SL, Pear WS, Faryabi RB.: EBF1 nuclear repositioning instructs chromatin refolding to promote therapy resistance in T leukemic cells. Mol Cell 82(5): 1003-1020, Mar 2022.
108 Schwartz GW, Zhou Y, Petrovic J, Pear WS, Faryabi RB.: TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes. Cell Rep 36: 109575, Aug 2021.
1a5 Zheng Q, Capell BC, Parekh V, O'Day C, Atillasoy C, Bashir HM, Yeh C, Shim EH, Prouty SM, Dentchev T, Lee V, Wushanley L, Kweon Y, Suzuki-Horiuchi Y, Pear W, Grice EA, Seykora JT.: Whole-Exome and Transcriptome Analysis of UV-Exposed Epidermis and Carcinoma In Situ Reveals Early Drivers of Carcinogenesis. J Invest Dermatol 141: 295-307, Feb 2021.
1c9 Kobia FM, Preusse K, Dai Q, Weaver N, Hass MR, Chaturvedi P, Stein SJ, Pear WS, Yuan Z, Kovall RA, Kuang Y, Eafergen N, Sprinzak D, Gebelein B, Brunskill EW, Kopan R.: Notch dimerization and gene dosage are important for normal heart development, intestinal stem cell maintenance, and splenic marginal zone B-cell homeostasis during mite infestation. PLoS Biol 18: e3000850, Oct 2020.
c1 Zhang W, Pear WS.: MYC degradation via AURKB inhibition: a new brake in the path to T-ALL. Blood Sci 2: 68-69, May 2020.
183 Rome KS, Stein SJ, Kurachi M, Petrovic J, Schwartz GW, Mack EA, Uljon S, Wu WW, DeHart AG, McClory SE, Xu L, Gimotty PA, Blacklow SC, Faryabi RB, Wherry EJ, Jordan MS, Pear WS.: Trib1 regulates T cell differentiation during chronic infection by restraining the effector program. J Exp Med 217: e20190888, May 2020.
14e Schwartz Gregory W, Zhou Yeqiao, Petrovic Jelena, Fasolino Maria, Xu Lanwei, Shaffer Sydney M, Pear Warren S, Vahedi Golnaz, Faryabi Robert B: TooManyCells identifies and visualizes relationships of single-cell clades. Nature Methods 17(4): 405-413, April 2020.
2c